Clinical Trial Results:
Estudio fase II abierto, no aleatorizado, de erlotinib en combinación con gemcitabina en pacientes con adenocarcinoma de páncreas avanzado irresecable o metastásico: relación entre rash cutáneo y supervivencia.
[A Phase II, open-label, non-randomized study of erlotinib in combination with gemcitabine in patients with advanced unresectable or metastatic adenocarcinoma of the pancreas: relation between cutaneous rash and survival].
Summary
|
|
EudraCT number |
2006-001518-34 |
Trial protocol |
ES |
Global completion date |
23 Mar 2010
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
31 Jan 2016
|
First version publication date |
31 Jan 2016
|
Other versions |
|
Summary report(s) |
CTg Receipt ML20296 |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.